155 related articles for article (PubMed ID: 16263332)
21. Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells.
Sellner L; Stiefelhagen M; Kleinschmidt JA; Laufs S; Wenz F; Fruehauf S; Zeller WJ; Veldwijk MR
Exp Hematol; 2008 Aug; 36(8):957-64. PubMed ID: 18495326
[TBL] [Abstract][Full Text] [Related]
22. An in silico immunological approach for prediction of CD8+ T cell epitopes of Leishmania major proteins in susceptible BALB/c and resistant C57BL/6 murine models of infection.
Guerfali FZ; Ben-Abdallah H; Sghaier RM; Ben-Aissa K; Mkannez G; Attia H; Laouini D
Infect Genet Evol; 2009 May; 9(3):344-50. PubMed ID: 18420466
[TBL] [Abstract][Full Text] [Related]
23. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
Dobaño C; Doolan DL
Mol Immunol; 2007 Apr; 44(11):3037-48. PubMed ID: 17303242
[TBL] [Abstract][Full Text] [Related]
24. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
Zaiss AK; Muruve DA
Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
[TBL] [Abstract][Full Text] [Related]
25. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice.
Ma H; Liu Y; Liu S; Xu R; Zheng D
Hepatology; 2005 Dec; 42(6):1355-63. PubMed ID: 16317690
[TBL] [Abstract][Full Text] [Related]
26. Tailoring the AAV vector capsid for gene therapy.
Vandenberghe LH; Wilson JM; Gao G
Gene Ther; 2009 Mar; 16(3):311-9. PubMed ID: 19052631
[TBL] [Abstract][Full Text] [Related]
27. Recent developments in adeno-associated virus vector technology.
Büning H; Perabo L; Coutelle O; Quadt-Humme S; Hallek M
J Gene Med; 2008 Jul; 10(7):717-33. PubMed ID: 18452237
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel foot-and-mouth disease virus specific T-cell epitopes in c/c and d/d haplotype miniature swine.
Gerner W; Denyer MS; Takamatsu HH; Wileman TE; Wiesmüller KH; Pfaff E; Saalmüller A
Virus Res; 2006 Nov; 121(2):223-8. PubMed ID: 16934904
[TBL] [Abstract][Full Text] [Related]
29. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.
Veron P; Leborgne C; Monteilhet V; Boutin S; Martin S; Moullier P; Masurier C
J Immunol; 2012 Jun; 188(12):6418-24. PubMed ID: 22593612
[TBL] [Abstract][Full Text] [Related]
30. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
[TBL] [Abstract][Full Text] [Related]
31. Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice.
Li H; Tuyishime S; Wu TL; Giles-Davis W; Zhou D; Xiao W; High KA; Ertl HC
Mol Ther; 2011 Mar; 19(3):536-46. PubMed ID: 21157435
[TBL] [Abstract][Full Text] [Related]
32. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.
Wu TL; Li H; Faust SM; Chi E; Zhou S; Wright F; High KA; Ertl HC
Mol Ther; 2014 Jan; 22(1):42-51. PubMed ID: 24077034
[TBL] [Abstract][Full Text] [Related]
33. Detection and characterization of functional T-cell epitopes on the structural proteins VP2, VP3, and VP4 of foot and mouth disease virus O1 campos.
Pérez Filgueira M; Wigdorovitz A; Romera A; Zamorano P; Borca MV; Sadir AM
Virology; 2000 Jun; 271(2):234-9. PubMed ID: 10860876
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
[TBL] [Abstract][Full Text] [Related]
35. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes.
Maersch S; Huber A; Büning H; Hallek M; Perabo L
Virology; 2010 Feb; 397(1):167-75. PubMed ID: 19926109
[TBL] [Abstract][Full Text] [Related]
36. AAV display--homing in on the target.
Lieber A
Nat Biotechnol; 2003 Sep; 21(9):1011-3. PubMed ID: 12949562
[No Abstract] [Full Text] [Related]
37. AAV-based gene transfer.
Büning H; Nicklin SA; Perabo L; Hallek M; Baker AH
Curr Opin Mol Ther; 2003 Aug; 5(4):367-75. PubMed ID: 14513679
[TBL] [Abstract][Full Text] [Related]
38. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
[TBL] [Abstract][Full Text] [Related]
39. Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions
Pei X; Earley LF; He Y; Chen X; Hall NE; Samulski RJ; Li C
Front Immunol; 2018; 9():844. PubMed ID: 29725339
[TBL] [Abstract][Full Text] [Related]
40. The HLA class I immunopeptidomes of AAV capsid proteins.
Brito-Sierra CA; Lannan MB; Malherbe LP; Siegel RW
Front Immunol; 2023; 14():1212136. PubMed ID: 37662941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
